Oncology/Hematology
Lung Cancer
More in Lung Cancer
Also from SNO: TTFields boosts PFS in glioblastoma, proton therapy for leptomeningeal disease
Nov 25, 2024
Largest survival benefit observed in patients who entered a cessation program within 6 months
Oct 31, 2024
Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone
Oct 10, 2024
1.00
CME Credits